Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) was the recipient of a large decrease in short interest in February. As of February 14th, there was short interest totalling 169,900 shares, a decrease of 43.2% from the January 30th total of 298,900 shares. Based on an average trading volume of 260,100 shares, the short-interest ratio is currently 0.7 days. Approximately 1.0% of the shares of the company are short sold.
Several research firms have commented on CYCC. Zacks Investment Research cut Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 14th. ValuEngine raised Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd.
Shares of CYCC traded down $0.01 during mid-day trading on Friday, reaching $0.53. The company had a trading volume of 93,800 shares, compared to its average volume of 228,402. Cyclacel Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $1.18. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.65 and a quick ratio of 7.65. The company’s 50-day moving average is $0.74 and its 200-day moving average is $0.53. The company has a market capitalization of $10.53 million, a P/E ratio of -0.95 and a beta of 3.11.
An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC lifted its stake in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 8.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,269,326 shares of the biotechnology company’s stock after buying an additional 98,364 shares during the period. Renaissance Technologies LLC owned about 7.38% of Cyclacel Pharmaceuticals worth $850,000 at the end of the most recent reporting period. Institutional investors own 9.45% of the company’s stock.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
See Also: How to Invest in an Index Fund
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.